Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study

Journal:

Journal of Clinical Oncology

Published:

2026-01-17

DOI:

10.1200/jco-25-01548

Affiliations:

12

Authors:

17

Go to article

Institutions	Authors	Share
AstraZeneca, United Kingdom (UK)	7.000000	0.41
Royal Derby Hospital, United Kingdom (UK)	2.000000	0.12
Simon Khechinashvili University Clinic, Georgia	1.000000	0.06
Israeli - Georgian Medical Research Clinic Healthycore LTD, Georgia	1.000000	0.06
Academician Fridon Todua Medical Center, Georgia	1.000000	0.06
LTD High Technology Hospital Med Center, Georgia	1.000000	0.06
National Institute of Cancer (INCan), Mexico	1.000000	0.06
The University of Nottingham (UoN), United Kingdom (UK)	1.000000	0.06
AstraZeneca United States, United States of America (USA)	1.000000	0.06
The Institute of Clinical Oncology, Georgia	1.000000	0.06

Interested in Oncology and Carcinogenesis?